Pepex Biomedical Receives Approval on a Series of Critical New Patents
Summary
Beyond blood glucose, Pepex plans to employ its proprietary Aerosol Jet Printing (AJP) manufacturing methodology to apply newly developed chemistry capable of detecting the COVID-19 antigen and antibody. The Company’s "in tissue" biosensor is a critical component of the previously announced project to commercialize four test products designed to provide safe, accurate measurement results within minutes. Furthermore, this revolutionary achievement ensures Pepex global exclusivity regarding its proprietary printing processes to deliver biosensors as small and accurate as those the Company will produce.“Even though there are no at-home meters capable of producing a true blood glucose reading - only a lab test can do that – the breakthrough technology represented by our most recent worldwide patent award provides us the unique capability to analyze samples ‘in tissue’ which essentially eliminates any potential systemic dysfunction,” said Paul Danner, Chief Executive Officer of Pepex Biomedical. With our latest technology, we expect to reduce that variance to nearly zero,” he added.Beyond blood glucose, Pepex plans to employ its proprietary Aerosol Jet Printing (AJP) manufacturing methodology to apply newly developed chemistry capable of detecting the COVID-19 antigen and antibody. The Company’s "in tissue" biosensor is a critical component of the previously announced project to commercialize four test products designed to provide safe, accurate measurement results within minutes.